GIM
REGN icon

Glenmede Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Glenmede Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$8.45M Buy
15,031
+8,952
+147% +$5.06M 0.04% 376
2025
Q2 		$3.19M Buy
+6,079
New +$3.39M 0.02% 506

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Glenmede Investment Management's REGN Position: Q3 2025 in Review

Glenmede Investment Management increased its Regeneron Pharmaceuticals (REGN) stake by 147% in Q3 2025, buying an estimated $5.06M and bringing the position to 15,031 shares worth $8.45M. The position accounts for 0.04% of the portfolio, ranked #376.

Glenmede Investment Management first reported a position in REGN in Q2 2025 and has held it in 2 quarters since. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • Glenmede Investment Management held 15,031 shares of Regeneron Pharmaceuticals worth $8.45M as of Q3 2025.
  • Glenmede Investment Management bought 8,952 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $5.06M.
  • Regeneron Pharmaceuticals made up 0.04% of Glenmede Investment Management's portfolio in Q3 2025, its #376 holding.
  • Glenmede Investment Management first reported a position in Regeneron Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.